Exact Sciences (EXAS) Stock Price
Exact Sciences Price
Over the last 19 years Exact Sciences grew revenue by 41.0% annually, reaching 3.25 B USD. For Exact Sciences, the net margin of -6.4% is up versus -33.7% a few years ago. The consensus 12-month price target for Exact Sciences is 107.10 USD, about 2.1% above where the stock trades today. Of 29 analysts, 8 rate the stock a buy — an overall Hold consensus.
Exact Sciences stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Exact Sciences business model & stock analysis
Frequently asked questions about Exact Sciences
The business model of Exact Sciences Corp involves developing and commercializing non-invasive screening tests for the detection and prevention of colorectal cancer. The company utilizes advanced molecular diagnostics and genomics to provide accurate and early detection of cancer. Through their flagship product, Cologuard, Exact Sciences offers individuals a convenient, at-home stool-based DNA test that detects both colorectal cancer and pre-cancerous polyps. By focusing on this niche market, Exact Sciences aims to improve cancer screening compliance and reduce mortality rates associated with colorectal cancer. With their innovative approach and commitment to patient care, Exact Sciences Corp continues to make significant strides in the field of cancer diagnostics.
The primary industries in which Exact Sciences Corp is active include healthcare, medical diagnostics, and biotechnology.
The main competitors of Exact Sciences Corp in the market are companies such as Myriad Genetics, Guardant Health, and Illumina.
Exact Sciences Corp is a renowned biotech company headquartered in Madison, Wisconsin. Established in 1995, Exact Sciences focuses on developing innovative molecular diagnostic tests to detect and prevent various types of cancer, with a primary emphasis on colorectal cancer. The company's flagship product, Cologuard, is a non-invasive, FDA-approved screening test offering a convenient and accurate alternative to traditional colonoscopies. Exact Sciences has garnered significant recognition in the medical community for advancing cancer detection and has witnessed substantial growth in recent years. With its commitment to improving patient outcomes, Exact Sciences Corp continues to be at the forefront of diagnostic innovation in the fight against cancer.
Exact Sciences Corp has achieved several significant milestones in its history. One notable milestone is the development and successful launch of their flagship product, Cologuard. This non-invasive, at-home colon cancer screening test has revolutionized the early detection and prevention of colon cancer. Another milestone for the company was the achievement of FDA approval for Cologuard, establishing it as a reliable and accurate screening option. Exact Sciences Corp also entered into strategic partnerships and collaborations, such as the collaboration with Pfizer to develop and commercialize blood-based screening tests for multiple types of cancers. These milestones highlight the company's dedication to advancing cancer screening and improving patient outcomes.
Exact Sciences Corp is primarily present in the United States.
Exact Sciences Corp represents a strong commitment to improving and advancing cancer detection and treatment. The company is dedicated to saving lives by providing innovative and accurate diagnostic tests, primarily focused on colorectal cancer. Exact Sciences Corp strives to deliver reliable results and empower healthcare professionals and patients with advanced screening options, such as the non-invasive Cologuard test. With a mission to make a difference in the fight against cancer, Exact Sciences Corp aims to enhance early detection rates, improve patient outcomes, and ultimately contribute to a world where cancer is prevented or detected at its earliest stages.
Analysts currently set an average price target of 103.87 USD for the Exact Sciences stock (median: 107.10 USD), implying -1.0 % versus the latest price. The consensus is based on 29 analyst ratings.
29 analysts currently rate the Exact Sciences stock: 8 recommend buying, 21 holding and 0 selling. For 2026, analysts expect Exact Sciences to generate revenue of 3.66 B USD and earnings per share of 0.92 USD.
Converted at the current exchange rate, the Exact Sciences share trades at 93.53 EUR (104.91 USD).
The Exact Sciences share (EXAS) is listed on 5 stock exchanges, including: NASDAQ (EXAS), SIX (Zürich) (EXK.SW), Frankfurt (EXK.F), München (EXK.MU), Düsseldorf (EXK.DU).
Exact Sciences Corporation is a leading company in cancer research and develops innovative diagnostic tests and products to detect cancer at an early stage. The company was founded in 1995 and is headquartered in Madison, Wisconsin. The business activities of Exact Sciences Corporation are divided into two divisions: diagnostic products and genomics products. Diagnostic Products: The flagship product of Exact Sciences Corporation is the Cologuard test, which was approved in 2014. Cologuard is a non-invasive test for the early detection of colorectal cancer. The test uses a combination of DNA and protein analysis to detect genetic changes and other biomarkers that could indicate cancerous changes in the colon. The test is prescribed by doctors and is performed in laboratories by Exact Sciences Corporation. Other diagnostic products of Exact Sciences Corporation include the Oncotype DX Breast Recurrence Score and the Oncotype DX Colon Recurrence Score. These tests are specifically designed for breast and colon cancer patients to predict the likelihood of tumor recurrence. Genomics Products: Exact Sciences Corporation also offers a range of genomics products, which were integrated into the business model following the acquisition of Genomic Health in 2019. These products include the Oncotype DX Breast Test and the Oncotype DX Prostate Test. The Oncotype DX Breast Test uses genomic technologies to determine the likelihood that a breast cancer patient will benefit from chemotherapy. The Oncotype DX Prostate Test assists doctors in deciding whether active surveillance or aggressive treatment is best suited for patients with prostate cancer. In summary, Exact Sciences Corporation is focused on innovation in cancer research. The company aims to improve the early detection of cancer and optimize treatment outcomes. With its diagnostic and genomic products, Exact Sciences Corporation continues to expand its reputation as a leading company in cancer research.
The expected revenue of Exact Sciences is 3.66 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Exact Sciences is 173.64 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Exact Sciences is currently 114.64. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Exact Sciences stock.
The price-to-sales ratio (P/S) of Exact Sciences is currently 5.44. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Exact Sciences stock.
The Eulerpool Quality Score for Exact Sciences is 4/10.
The ISIN of Exact Sciences is US30063P1057. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Exact Sciences is 590273. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Exact Sciences is EXAS. The ticker symbol is used to trade Exact Sciences shares on the stock exchange.
Exact Sciences stock
Exact Sciences Peer Group
Exact Sciences Ticker
Exact Sciences FIGI
All fundamentals and in-depth analysis of Exact Sciences
Our stock analysis for Exact Sciences stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Exact Sciences. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.